<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/64E99764-A3A6-4794-B81C-B0F1CC0A01EB"><gtr:id>64E99764-A3A6-4794-B81C-B0F1CC0A01EB</gtr:id><gtr:name>Creative Antibiotics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Cellular and Molecular Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/64E99764-A3A6-4794-B81C-B0F1CC0A01EB"><gtr:id>64E99764-A3A6-4794-B81C-B0F1CC0A01EB</gtr:id><gtr:name>Creative Antibiotics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/52818C77-4685-4862-8524-ECA0EA07CC3D"><gtr:id>52818C77-4685-4862-8524-ECA0EA07CC3D</gtr:id><gtr:firstName>Ariel</gtr:firstName><gtr:otherNames>Judith</gtr:otherNames><gtr:surname>Blocker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701243"><gtr:id>A9E2D4FD-3538-421F-A778-31A7667522F1</gtr:id><gtr:title>Functional analysis of the Shigella flexneri type III secretion system distal needle tip complex</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701243</gtr:grantReference><gtr:abstractText>Many disease-causing bacteria attack the cells our bodies by using a complex machine designed to inject bacterial toxins directly into the attacked cell. This machine directly contacts the targeted cell by using a tiny hollow needle that projects from the surface of the bacterium. Contact between the cell and the needle switches on the machine within the bacterium so that bacterial toxins travel through the needle and are injected into the cell. We want to study the detailed structure of this needle, and in particular of its external tip, to help us understand how the bacterium knows that the needle has touched a suitable host cell. We then want to understand how the needle tip alters itself to insert into the cell and allow passage of the relatively large bacterial toxins through the narrow central channel of the needle. We hope that a good understanding of this system will suggest new ways to interfere with the process. Such knowledge may lead to the eventual design of novel antimicrobials and vaccines at a time when antibiotic resistance is increasing ever faster.</gtr:abstractText><gtr:technicalSummary>Type III secretion systems (T3SSs) are essential virulence determinants of many Gram-negative bacterial pathogens of animals and plants. We study the T3SS of Shigella flexneri, an agent of bacillary dysentery in humans, as a model to understand key functional mechanisms of T3SS. The Shigella T3SS consists of a cytoplasmic bulb, a transmembrane region and a hollow needle protruding from the bacterial surface. Physical contact with eukaryotic host cells initiates secretion and leads to formation of a pore, formed by the bacterial proteins IpaB and IpaC, in the host-cell membrane. Through this pore, further bacterial proteins, termed effectors and facilitating host cell invasion, are translocated. Understanding the molecular details of this protein transport process, the core function of all T3SSs, is the focus of our laboratory. We showed that the needle is implicated in host cell sensing and secretion regulation and that its distal tip contains components that initiate host cell contact. Through biochemical and immunological studies of wild-type and mutant Shigella T3SS needles, we revealed tip complexes of differing compositions and functional states, that appear to represent the molecular events surrounding host cell sensing and pore formation. The interaction between IpaD and IpaB at needle tips is key to host cell sensing, orchestration of IpaC secretion and its subsequent assembly at needle tips. This allows insertion into the host cell membrane of a translocation pore that is continuous with the needle and its secretion channel and hence direct effector translocation.
Our present goal is to investigate crucial aspects of our new working model. This can be subdivided into:
1) Understanding the molecular mechanism of mature tip complex assembly prior to host cell contact. 
2) Determining the physiological mechanism of tip complex activation for secretion. 
3) Investigating the development of any conformational changes within the tip complex during artificial or physiological activation and translocon insertion. 
This work is key to understand all T3SSs because the needle, the translocon and the IpaD-type adaptor are highly conserved components. IpaD homologues in other T3SSs are so far the only T3SS components to which disease-protecting antibodies can be raised. Understanding the molecular mechanism of T3SS activation also offers the possibility of rational drug design, an appealing option given ever increasing antiboitic resistance in bacteria.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>298220</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Creative Antibiotics</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Identification of molecular target of small molecule T3SS inhibitors</gtr:description><gtr:id>ECAA484C-D2BD-4A65-98B3-51BA610A5820</gtr:id><gtr:impact>We believe we have identified the targets of the these drugs using a genetic screen and whole genome sequencing. This work is now published in PLoS One.</gtr:impact><gtr:partnerContribution>Company gave inhibitory compounds to be tested.</gtr:partnerContribution><gtr:piContribution>We studied the effects of the compounds on Shigella flexneri and Salmonella typhimurium T3SS-related systems and have published one paper on the Shigella work already (PMID: 18996990), whilst the Salmonella work (PMID:23300965). Thus, this work in an indirect consequence of having MRC funding to support my lab in general. It paid for some of the consumables used by an EEC funded postdoc and a technician to do the work and it also supported part of the salary of the part-time technician.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Rational design of peptide inhibitors of T3SS activation</gtr:description><gtr:id>FCC7D227-7CCA-4CBA-9BA1-D791B4156308</gtr:id><gtr:impact>Inhibitors did not work</gtr:impact><gtr:partnerContribution>Assistance with design of peptides to be tested. Purchase of peptides to be tested. Synthesis, purification and characterisation of some peptides. Assistance with project progress through MRCT assessment and development scheme.</gtr:partnerContribution><gtr:piContribution>Basic research underlying virulence mechanism to be targeted. ELISA based T3SS induction assay and technical personnel time.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Rational design of peptide inhibitors of T3SS activation</gtr:description><gtr:id>79248132-7FDF-4535-A5CE-92DF37294C17</gtr:id><gtr:impact>Inhibitors did not work</gtr:impact><gtr:partnerContribution>Assistance with design of peptides to be tested. Purchase of peptides to be tested. Synthesis, purification and characterisation of some peptides. Assistance with project progress through MRCT assessment and development scheme.</gtr:partnerContribution><gtr:piContribution>Basic research underlying virulence mechanism to be targeted. ELISA based T3SS induction assay and technical personnel time.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visits-South Gloucestershire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1D07B92D-3581-4171-BECC-F13CF6826918</gtr:id><gtr:impact>~10 International Baccalaureate students attended lecture by PI as a supplement to their Biology course.
Postdoc ran a session on basic Microbiology in a primary school.
PI ran session on Infectious Diseases using Hollywood film &amp;quot;Contagion&amp;quot; for year 7-8 children.

Schools asked us back and we are now visiting other schools locally.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>School of Cellular and Molecular Medicine</gtr:department><gtr:description>Awarded departmental PhD studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>University of Bristol</gtr:fundingOrg><gtr:id>1BBDFE91-4276-4723-82F7-3BF7CAA89C30</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant MR/J002097/1</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J002097/1</gtr:fundingRef><gtr:id>DEC75FE5-6B10-46F8-80B8-4ACFF458EC0A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SGM Undergraduate Student Vacation Scholarship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Society of General Microbiology</gtr:fundingOrg><gtr:id>00B4F5E4-9A4D-4E21-9955-47594CB719B1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107471</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant WT082398 High resolution electron microscopy studies of the Shigella T3SS needle distal tip complex</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>WT082398</gtr:fundingRef><gtr:id>544F4C62-061A-45D7-AF1E-7C94988AB568</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust New Investigator Award WT104634AIA</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>WT104634AIA</gtr:fundingRef><gtr:id>5273F9DC-C8C9-472E-86AC-B47A7A1DB5DA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The EM maps and pseudoatomic model were deposited in the Electron Microscopy Data Bank and the Protein Data Bank under accession numbers EMD-2801, EMD-2802, EMD-2803, EMD-2804, EMD-2806, EMD-2805 and 4D3E, respectively.</gtr:description><gtr:id>4663CF69-384A-4F88-B521-8BB86468DEA9</gtr:id><gtr:impact>Too early to say</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>20 A electron density maps of the T3SS distal needle tip complex and docked pseudoatomic model of IpaD tretramer</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Set of programmes, instructions and test data sets released via MRC funded CCPEM and University of Bristol Data Repository (10.5523/bris.1trtuj35bwn5410ibhinps47ag)</gtr:description><gtr:id>400FAC80-45DF-41C7-866E-561F3C933D55</gtr:id><gtr:impact>Too early to say</gtr:impact><gtr:openSourceLicense>true</gtr:openSourceLicense><gtr:title>Bespoke programmes for 3D reconstruction of T3SS distal needle tip complex</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.ccpem.ac.uk/download.php</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Creative Antibiotics</gtr:companyName><gtr:description>Creative Antibiotics is developing virulence blockers which can be alternative or complementary to current antibiotics.
Currently, Creative Antibiotics has three projects: agents against infections in severe burns, agents against diarrhoea and agents against chlamydia infections.
http://www.creativeantibiotics.com/default.asp?LID=1</gtr:description><gtr:id>CC1F7C80-C18F-4F81-B788-769AB71510E5</gtr:id><gtr:impact>Tried to use our understanding of T3SS distal needle tip complex to help company design better PcrV inhibitors.
Unfortunately, they went out of business in June 2013.</gtr:impact><gtr:url>http://www.creativeantibiotics.com/default.asp?LID=1</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFDDC767-9545-417E-8935-7ABDFFBD7657"><gtr:id>AFDDC767-9545-417E-8935-7ABDFFBD7657</gtr:id><gtr:title>Needle length control and the secretion substrate specificity switch are only loosely coupled in the type III secretion apparatus of Shigella.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1821d010cd54d8ecb9d6602117d8259"><gtr:id>f1821d010cd54d8ecb9d6602117d8259</gtr:id><gtr:otherNames>Shen DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18211742-D345-43F2-995C-7B06ED8E6144"><gtr:id>18211742-D345-43F2-995C-7B06ED8E6144</gtr:id><gtr:title>Domains of the Shigella flexneri type III secretion system IpaB protein involved in secretion regulation.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1821d010cd54d8ecb9d6602117d8259"><gtr:id>f1821d010cd54d8ecb9d6602117d8259</gtr:id><gtr:otherNames>Shen DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2FF61CCC-D3D3-41D5-B91B-99BE320DEB7D"><gtr:id>2FF61CCC-D3D3-41D5-B91B-99BE320DEB7D</gtr:id><gtr:title>The extreme C terminus of Shigella flexneri IpaB is required for regulation of type III secretion, needle tip composition, and binding.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5819d8771dad9f02d80ca1d61fdacca1"><gtr:id>5819d8771dad9f02d80ca1d61fdacca1</gtr:id><gtr:otherNames>Roehrich AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC61249B-4959-43FB-84F9-2FE387764D2E"><gtr:id>CC61249B-4959-43FB-84F9-2FE387764D2E</gtr:id><gtr:title>Shigella IpaD has a dual role: signal transduction from the type III secretion system needle tip and intracellular secretion regulation.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5819d8771dad9f02d80ca1d61fdacca1"><gtr:id>5819d8771dad9f02d80ca1d61fdacca1</gtr:id><gtr:otherNames>Roehrich AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/039567D0-3D50-402B-92CE-E05950AE4814"><gtr:id>039567D0-3D50-402B-92CE-E05950AE4814</gtr:id><gtr:title>Isolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella-mediated motility.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8c63d62e17b9d548a7102927d64372af"><gtr:id>8c63d62e17b9d548a7102927d64372af</gtr:id><gtr:otherNames>Martinez-Argudo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E600EAE-66F5-467D-88BB-D26A43C53C0E"><gtr:id>5E600EAE-66F5-467D-88BB-D26A43C53C0E</gtr:id><gtr:title>Three-dimensional electron microscopy reconstruction and cysteine-mediated crosslinking provide a model of the type III secretion system needle tip complex.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b55a72c02e4acccae8011ab33b5657bd"><gtr:id>b55a72c02e4acccae8011ab33b5657bd</gtr:id><gtr:otherNames>Cheung M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/172F5708-5585-4A21-B665-414C68606805"><gtr:id>172F5708-5585-4A21-B665-414C68606805</gtr:id><gtr:title>Genetic Dissection of the Signaling Cascade that Controls Activation of the Shigella Type III Secretion System from the Needle Tip.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/094ac6545dce3343a075923a164afc4b"><gtr:id>094ac6545dce3343a075923a164afc4b</gtr:id><gtr:otherNames>Murillo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701243</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>